Published in Eur Respir J on March 23, 2014
Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J (2015) 6.18
Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. MBio (2014) 1.43
Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. Genome Med (2015) 1.21
Clinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases. J Clin Microbiol (2015) 1.10
Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance. Nat Genet (2016) 1.09
The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet (2016) 0.90
Multidrug-resistant tuberculosis in Europe, 2010-2011. Emerg Infect Dis (2015) 0.84
The role of delamanid in the treatment of drug-resistant tuberculosis. Ther Clin Risk Manag (2015) 0.83
Clinical use of whole genome sequencing for Mycobacterium tuberculosis. BMC Med (2016) 0.83
Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings. Trans R Soc Trop Med Hyg (2016) 0.83
Breakpoints and drug exposure are inevitably closely linked. Antimicrob Agents Chemother (2015) 0.82
Time to culture positivity and sputum smear microscopy during tuberculosis therapy. PLoS One (2014) 0.82
New Antituberculosis Drugs: From Clinical Trial to Programmatic Use. Infect Dis Rep (2016) 0.81
Medical Management of Drug-Resistant Tuberculosis. Tuberc Respir Dis (Seoul) (2015) 0.79
IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection. Sci Rep (2015) 0.78
Drug-resistant tuberculosis in Eastern Europe: challenges and ways forward. Public Health Action (2014) 0.78
Extensively Drug-Resistant Tuberculosis: Report and Literature Review on Two Cases Requiring Prolonged Treatment. Am J Case Rep (2016) 0.75
Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother (2015) 0.75
Tuberculous pleural effusion. J Thorac Dis (2016) 0.75
Emergence of mixed infection of Beijing/Non-Beijing strains among multi-drug resistant Mycobacterium tuberculosis in Pakistan. 3 Biotech (2016) 0.75
Predictors of Prolonged TB Treatment in a Dutch Outpatient Setting. PLoS One (2016) 0.75
Reduced chance of hearing loss associated with Therapeutic Drug Monitoring of Aminoglycosides in the treatment of Multidrug Resistant Tuberculosis. Antimicrob Agents Chemother (2017) 0.75
Recurrence after Successful Treatment of Multidrug-Resistant Tuberculosis in Taiwan. PLoS One (2017) 0.75
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. BMC Health Serv Res (2017) 0.75
Good news about a bad subject: scientific evidence to help defeat multidrug/extensively drug-resistant tuberculosis. Eur Respir J (2014) 0.75
Combined antigen-specific interferon-γ and interleukin-2 release assay (FluoroSpot) for the diagnosis of Mycobacterium tuberculosis infection. PLoS One (2015) 0.75
First use of bedaquiline in a patient with XDR-TB in Singapore. BMJ Case Rep (2015) 0.75
Outcomes of multidrug-resistant tuberculosis in Zambia: a cohort analysis. Infection (2017) 0.75
Genotypic distribution of multidrug-resistant and extensively drug-resistant tuberculosis in northern Thailand. Infect Drug Resist (2017) 0.75
Comments on Ren et al.: Is duration of preoperative anti-tuberculosis treatment a risk factor for postoperative relapse or non-healing of spinal tuberculosis? Eur Spine J (2016) 0.75
Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India. Public Health Action (2017) 0.75
Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients. Antimicrob Agents Chemother (2017) 0.75
The Tuberculosis Network European Trials Group (TBNET): new directions in the management of tuberculosis. Breathe (Sheff) (2017) 0.75
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med (2007) 33.18
Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med (2010) 32.89
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet (2006) 21.60
The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature (1992) 11.99
Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis (1998) 11.56
Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet (2010) 10.21
Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet (1999) 10.06
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J (2011) 8.96
Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep (2005) 8.91
Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis (2009) 6.81
Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet (2012) 6.78
Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med (2012) 6.73
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet (2012) 6.70
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med (2011) 6.42
National survey of drug-resistant tuberculosis in China. N Engl J Med (2012) 6.28
Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med (2003) 6.07
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev (2013) 5.78
The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med (2009) 5.78
HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis (2007) 5.40
Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med (2011) 5.31
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis (2010) 5.14
Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med (2010) 5.01
Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet (2010) 4.95
HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med (2009) 4.76
High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet (2011) 4.73
Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med (2012) 4.69
Transmission of tubercle bacilli: The effects of chemotherapy. Tubercle (1976) 4.53
Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis (1999) 4.52
Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep (2005) 4.36
Totally drug-resistant tuberculosis in India. Clin Infect Dis (2011) 4.31
Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis (2009) 4.22
Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ (2011) 4.19
Infectiousness of air from a tuberculosis ward. Ultraviolet irradiation of infected air: comparative infectiousness of different patients. Am Rev Respir Dis (1962) 4.15
Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Chest (2009) 4.11
Drug-resistant tuberculosis, clinical virulence, and the dominance of the Beijing strain family in Russia. JAMA (2005) 3.89
Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax (2005) 3.81
A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis (2008) 3.77
Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet (2002) 3.67
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med (2009) 3.57
Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov (2013) 3.50
Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet (2010) 3.32
Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol (2006) 3.22
How contagious is tuberculosis? Clin Infect Dis (1996) 3.06
Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J (2012) 3.00
Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med (2006) 2.99
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis (2004) 2.95
Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J (2005) 2.93
Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol (2013) 2.89
Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol (2006) 2.88
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis (2006) 2.83
Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J (2010) 2.82
Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J Infect Dis (2007) 2.79
Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis (2006) 2.73
Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. Int J Tuberc Lung Dis (2000) 2.71
Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J (2012) 2.61
Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. Eur Respir J (2012) 2.58
Characteristics and early outcomes of patients with Xpert MTB/RIF-negative pulmonary tuberculosis diagnosed during screening before antiretroviral therapy. Clin Infect Dis (2012) 2.56
Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother (2009) 2.47
Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis (2012) 2.45
Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis (2010) 2.42
Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay--a clinical validation study. PLoS One (2011) 2.40
Aerial dissemination of pulmonary tuberculosis. A two-year study of contagion in a tuberculosis ward. 1959. Am J Epidemiol (1995) 2.40
Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur Respir J (2010) 2.38
A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics (2012) 2.36
Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J (2011) 2.33
Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis (2013) 2.29
Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother (2011) 2.29
Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol (1999) 2.26
Global tuberculosis drug development pipeline: the need and the reality. Lancet (2010) 2.26
Current evidence on diagnostic accuracy of commercially based nucleic acid amplification tests for the diagnosis of pulmonary tuberculosis. Thorax (2006) 2.20
Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis (2009) 2.19
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J (2012) 2.17
Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis (2013) 2.16
Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother (2009) 2.15
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother (2006) 2.14
Prolonged infectiousness of tuberculosis patients in a directly observed therapy short-course program with standardized therapy. Clin Infect Dis (2010) 2.11
Substandard and falsified anti-tuberculosis drugs: a preliminary field analysis. Int J Tuberc Lung Dis (2013) 2.11
Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bull World Health Organ (2007) 2.09
Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis (2012) 2.09
The infectiousness of tuberculosis patients coinfected with HIV. PLoS Med (2008) 2.08
Lifetime risks, incubation period, and serial interval of tuberculosis. Am J Epidemiol (2000) 2.05
Mycobacterium tuberculosis Beijing genotype and risk for treatment failure and relapse, Vietnam. Emerg Infect Dis (2003) 2.04
Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care. Int J Tuberc Lung Dis (2012) 2.03
Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol Microbiol (2002) 1.99
The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect (2011) 1.97
Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob Agents Chemother (2004) 1.96
Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. Lancet Infect Dis (2013) 1.96
Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One (2012) 1.93
A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis (2008) 1.91
Multidrug resistance among persons with tuberculosis in California, 1994-2003. JAMA (2005) 1.88
Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis (Edinb) (2012) 1.87
Mass incarceration can explain population increases in TB and multidrug-resistant TB in European and central Asian countries. Proc Natl Acad Sci U S A (2008) 1.86
Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother (2009) 1.82
Surgical face masks worn by patients with multidrug-resistant tuberculosis: impact on infectivity of air on a hospital ward. Am J Respir Crit Care Med (2012) 1.81
Microepidemics of tuberculosis: the stone-in-the-pond principle. Tuber Lung Dis (1992) 1.81
Treatment of tuberculosis: update 2010. Eur Respir J (2010) 1.79
In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother (2002) 1.75
LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J (2009) 3.16
Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J (2008) 2.43
Risk Assessment of Tuberculosis in Contacts by IFN-γ Release Assays. A Tuberculosis Network European Trials Group Study. Am J Respir Crit Care Med (2015) 1.71
A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. Tuberculosis (Edinb) (2011) 1.34
Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med (2014) 1.22
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. Int J Tuberc Lung Dis (2016) 1.01
Multidrug-resistant tuberculosis in Europe, 2010-2011. Emerg Infect Dis (2015) 0.84
Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey. Eur Respir J (2014) 0.84
False-negative interferon-γ release assay results in active tuberculosis: a TBNET study. Eur Respir J (2014) 0.84
MDR-TB and XDR-TB: drug resistance and treatment outcomes. Eur Respir J (2009) 0.82
Beyond multidrug-resistant tuberculosis in Europe: a TBNET study. Int J Tuberc Lung Dis (2015) 0.81
Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother (2009) 0.78
More on Treatment Outcomes in Multidrug-Resistant Tuberculosis. N Engl J Med (2016) 0.75
Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure. Am J Respir Crit Care Med (2017) 0.75